An international research team led by Dr. Trever Bivona of the University of California San Francisco (UCSF) identified a protein responsible for melanoma drug resistance. The study, published online in Nature Genetics, indicates a strategy to enhance the response to drug treatment and patient survival.
MRV Research
Two Cell-Signaling Molecules Found to Suppress the Spread of Melanoma
In what is believed to be the largest epigenetic analysis to date of cell-signaling molecules in early-stage melanoma, researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center have identified two tiny bits of non-coding genetic material in primary tumors that appear critical to stalling the cancer’s spread — and essentially setting the biological fate of the disease.
Novel Molecular Test Contributes to Definitive Diagnosis in Melanom
With a need to make more definitive diagnoses of melanocytic lesions, the Myriad myPath Melanoma molecular diagnostic test has been reported as a tool to calculate melanoma diagnostic scores (MDS) and help practitioners differentiate between benign and malignant lesions, according to results from a prospective study.
Two cell-signaling molecules found to suppress the spread of melanoma
In what is believed to be the largest epigenetic analysis to date of cell-signaling molecules in early-stage melanoma, researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center have identified two tiny bits of non-coding genetic material in primary tumors that appear critical to stalling the cancer’s spread—and essentially setting the biological fate of the disease.